Skip to main content
logo
VitaSpring Biomedical Co. Ltd. (VSBC)
OTCMKTS · Delayed Price · Currency is USD
0.0111
-0.2390 (-95.56%)
At close: Feb 12, 2026

VitaSpring Biomedical Financials Overview

Millions USD. Fiscal year is Feb - Jan.

Revenue & Profits
Chart
Fiscal YearTTMFY 2026FY 2025FY 2024FY 2023FY 2022
Period EndingApr '26 Jan '26 Jan '25 Jan '24 Jan '23 Jan '22
Revenue
-----5.61
Revenue Growth
-----2161.56%
Gross Profit
-----3.332.07
Operating Income
-0.39-0.38-0.68-1.11-4.181.13
Net Income
-0.41-0.42-0.77-1.12-4.160.91
Earnings Per Share
-0.00-0.00-0.00-0.01-0.020.00
EPS Growth
------

Cash & Debt
Chart
Fiscal YearCurrentFY 2026FY 2025FY 2024FY 2023FY 2022
Period EndingApr '26 Jan '26 Jan '25 Jan '24 Jan '23 Jan '22
Cash & Investments
0.01000.020.030.11
Total Debt
---0.090.260.46
Net Cash (Debt)
0.0100-0.07-0.23-0.36
Net Cash Growth
-666.18%----
Net Cash Per Share
0.000.00--0.00-0.00-0.00

Cash Flow & CapEx
Chart
Fiscal YearTTMFY 2026FY 2025FY 2024FY 2023FY 2022
Period EndingApr '26 Jan '26 Jan '25 Jan '24 Jan '23 Jan '22
Operating Cash Flow
0-0-0.01-0.03-0.08-0.27
Capital Expenditures
------0.07
Free Cash Flow
0-0-0.01-0.03-0.08-0.34
Free Cash Flow Growth
------

Margins
Chart
Fiscal YearTTMFY 2026FY 2025FY 2024FY 2023FY 2022
Period EndingApr '26 Jan '26 Jan '25 Jan '24 Jan '23 Jan '22
Gross Margin
-----36.84%
Operating Margin
-----20.07%
Pretax Margin
-----20.07%
Profit Margin
-----16.20%
FCF Margin
------6.10%

Valuation
Chart
Fiscal YearCurrentFY 2026FY 2025FY 2024FY 2023FY 2022
Period EndingAug '26 Jan '26 Jan '25 Jan '24 Jan '23 Jan '22
PE Ratio
-----3178.77
PS Ratio
-----515.09